Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetes Mellitus and HFrEF

Use of sodium–glucose co‐transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry

“…Although recommended by international guidelines on diabetes, SGLT2i are a relatively new treatment and the implementation of their use in clinical practice might require time. Previous data from the CHAMP‐HF study in the US showed that only 2% of the HF population with T2DM enrolled in this registry received SGLT2i between December 2015 and October 2017 17 . Our analysis of this nationwide Swedish cohort, where the universal health care system might lead to a more unbiased assessment of treatment in clinical practice, showed a considerable increase of SGLT2i use in HF patients since 2016, i.e.…”

Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials

“…Similarly, although it has been over 4 years since clinical trials have demonstrated benefits of SGLT2i in high-risk patients with type 2 diabetes, only 2% of HFrEF patients with comorbid diabetes are currently being treated with SGLT2i in clinical practice. [3][4][5]10,11 These gaps in evidence-based medical therapies have been implicated in relatively stagnant mortality trajectories of patients living with HFrEF. 12 Communication of the estimated treatment benefits of comprehensive disease-modifying pharmacologic therapy (ARNI, β-blocker, MRA, & SGLT2i) on clinical outcomes, especially if used over a lifetime, may facilitate decision-making by patients, clinicians, health systems, and payers.…”

Clinical application of sodium-glucose cotransporter 2 inhibitor into a real-world setting of heart failure care

“…Despite several methodological limitations this study highlights the incremental benefits of SGLT2 inhibitor added to guideline-directed HF-therapy in that patient population. Because of frequent incompleteness of guideline-directed HF-therapies in real-world clinical setting [7], however, it is necessary to determine whether the use of SGLT2 inhibitor before completion of guideline-directed HF-therapies is also beneficial. Furthermore, it is necessary to clarify the detailed patient population that can optimally gain clinical benefits from SGLT2 inhibitor therapy in real-world settings.…”